FDA DEEMS VAGUS NERVE THERAPY APPROVABLE AS A TREATMENT FOR DEPRESSION
On Feb 3, 2005 the U.S. Food and Drug Administration (FDA) notified the concern of the pneumogastric cheek stimulator (Cyberonics, Inc.) that it had deemed its VNS Therapy System approvable as a long-term adjunctive communication for patients over the geezerhood of 18 with habitual or continual treatment-resistant incurvation in a field sad program that has not responded to at small quaternary competent medication treatments. In the approvable honor conventional today by Cyberonics, bureau indicated that test support was contingent on test labeling, test protocols for a post-approval dosing improvement think and enduring registry.
This is an exceptional declaration and field travel for the quaternary meg Americans pain from habitual or treatment-resistant incurvation towards providing an FDA-approved, informatively labeled, long-term communication choice specifically for their long and life-threatening illness.
The bureau is reviewing the test labeling, which includes the Physician’s and Patient’s Manuals, and expects to rank that analyse in a opportune manner. When every of the FDA’s conditions hit been satisfied, the Company plans a conventional start in union with the dweller Psychiatric Association Annual Meeting in May.
You requirement to be your possess prizewinning exponent and civilize yourself most how this important bureau authorised therapy crapper modify your life. Learn more at www.VagusNerveStimulator.com
The communicator was a think think person in the bureau investigational effort of pneumogastric cheek input and habitual depression. He is the communicator of Out of the Negroid Hole: The Patient’s Guide to Vagus Nerve Stimulation and Depression and application of the VagusNerveStimulator.com Web site.
